tuvusertib + cemiplimab

This therapy is a **combination of tuvusertib** (also known as M1774), an **ATR (Ataxia Telangiectasia and Rad3-related protein) inhibitor** that targets the DNA damage response in cancer cells, and **cemiplimab**, a human monoclonal antibody that acts as a **PD-1 (programmed cell death protein 1) immune checkpoint inhibitor**. The combination is being investigated for synergistic antitumor effects, coupling enhanced DNA damage in tumor cells (via ATR inhibition by tuvusertib) with immune activation (via PD-1 inhibition by cemiplimab). Primary development is for **advanced non-squamous non-small cell lung cancer (NSCLC) in patients who have progressed on prior therapies**[1][2][3][4][5][6].

Brand names

Libtayo

Other names

anti-PD-1 cemiplimabanti-PD1 cemiplimabanti-PD 1 cemiplimab